RA Capital Management is a Boston-based investment firm that pursues evidence-based investing across public and private healthcare, life sciences, and planetary health sectors. The firm supports the growth of innovative companies from seed to later-stage financings, focusing on drugs, medical devices, diagnostics, biotech services, and research tools. RA Capital combines a data-driven research platform, TechAtlas, with a collaborative investment approach and a healthcare incubator, Raven, to help management teams advance ideas from inception through development and commercialization. It frequently co-invests, takes board seats, and participates in follow-on financings, aiming to back ventures that improve patient outcomes and reduce costs. The firm emphasizes US and European opportunities, maintains a multi-stage investment scope, and is headquartered in Boston.

MassVentures is a Massachusetts-based venture capital firm founded in 1978 that provides seed and early-stage funding to high-growth startups. It supports ventures as they move from concept to commercialization and offers mentorship, strategic guidance, and access to industry connections to help build scalable businesses. The firm backs innovations across quantum computing, clean energy, artificial intelligence, biotechnology, advanced materials, advanced manufacturing, and robotics, and operates programs such as MV Capital, MV Accelerate, and MV Spinouts to fund companies, accelerate commercialization, and translate academic research into viable enterprises. By leveraging the Massachusetts innovation ecosystem, MassVentures aims to bolster entrepreneurs outside traditional hubs and foster sustained growth within the regional economy.

General Catalyst is a venture capital firm founded in 2000 and headquartered in Cambridge, Massachusetts, with additional offices in North America and Europe. The firm backs companies from seed to growth stages and invests across technology sectors, including software, consumer and enterprise tech, fintech, crypto, healthcare, and AI-related ventures. General Catalyst provides not only capital but strategic guidance to help portfolio companies scale and innovate. Over the years it has managed multiple funds and built a global portfolio of technology businesses, aiming to support resilient growth and transformative technologies.

Alumni Ventures is a venture capital firm headquartered in Manchester, New Hampshire, that expands access to venture investing for accredited individuals by co-investing with leading venture capital firms and enabling participation through various structures such as funds, syndicates, and investment clubs. It collaborates with top firms including Andreessen Horowitz, Sequoia, and Y Combinator and supports opportunities across pre-seed to growth stages, across multiple sectors and geographies. The firm emphasizes rigorous due diligence, transparency, and diversification, leveraging a broad network of alumni investors and partners to connect founders with strategic capital and resources. With a global footprint and active involvement in the venture ecosystem, Alumni Ventures aims to broaden participation in venture capital while maintaining disciplined, founder-friendly investing.

Atlas Venture is a biotechnology-focused venture capital firm based in Cambridge, Massachusetts, with a long history dating back to 1980. The firm backs early-stage life sciences companies and technology startups, emphasizing seed-led venture creation and lead investing with board representation to help translate breakthrough science into medicines and medical technologies. Atlas partners with life science entrepreneurs across the United States and Europe, supporting companies in biopharmaceuticals, therapeutics, drug discovery platforms, diagnostics, medical devices, and related biotech innovations. The firm combines venture capital expertise with operational insight to build scalable companies, aiming to advance science from discovery to commercialization. Through its incubator and portfolio approach, Atlas has fostered numerous startups and maintains a focus on personalized medicine and next-generation biotech platforms.

Morningside is a venture capital firm based in the greater Boston area, founded in 1986 as a family office for the Chan family. It makes investments in companies developing novel science and technology across life sciences, digital health, artificial intelligence, materials and general technology, with a long-term, values-driven approach and a focus on ethical company-building. The team comprises investment professionals with deep sector experience, and the firm maintains charitable commitments to education, research and healthcare, supporting institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School and the MIT Morningside Academy for Design.

OrbiMed is a global healthcare investment firm focused on supporting the development of therapies, medical devices, diagnostics, and health IT. Established in 1989, it manages a broad investment platform across venture capital, private equity, and public equity, targeting opportunities from early-stage startups to mature companies. The firm backs companies across biopharmaceuticals, biotechnology, life sciences, and digital health, providing financing and strategic resources to accelerate innovation. With a multinational presence and offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, and beyond, OrbiMed pursues a diversified portfolio of healthcare companies worldwide.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

Founder Collective is a venture capital firm that backs seed and early-stage technology startups across sectors, with a focus on founder alignment, capital efficiency, and a long-term partnership approach. It supports companies from idea stage through IPO, emphasizing authentic founder–investor relationships, intrinsic value, and pragmatic, stage-focused investing. The firm is headquartered in Cambridge, Massachusetts, with offices in Boston and New York City, including the SoHo area, and operates across the United States and beyond. Founded in 2009 by a group of successful entrepreneurs, it is led by general partners Micah Rosenbloom, Amanda Herson, and David Frankel.

Flagship Pioneering is a venture capital firm based in Cambridge, Massachusetts, founded in 2000. The firm conceives, creates, resources, and grows first-in-category ventures to transform human health, sustainability, and related fields. It combines scientific invention, entrepreneurial leadership, and professional capital management in a single enterprise that systematically moves ideas from concept to company. Using an evolutionary methodology, Flagship advances biology, engineering, medicine, energy, and beyond by supporting teams that pursue seemingly unreasonable propositions and turn them into transformational businesses. The firm emphasizes people, process, and values to build enduring enterprises that address major global challenges, including health innovation, genetic medicines, and agricultural technologies. Flagship collaborates with industry and research partners to accelerate discovery and development, and its portfolio includes Moderna, Tessera Therapeutics, Generate:Biomedicines, Inari Agriculture, Quotient Therapeutics, and Lila Sciences.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California. It provides capital and operational support to technology and healthcare companies across stages from seed to IPO, with investments spanning software, consumer technology, medical devices, life sciences, AI, energy technology, and related sectors. The firm collaborates with founders on product development, market expansion, and navigating evolving markets, offering domain expertise alongside funding. With a long-standing track record of portfolio companies achieving IPOs and strategic acquisitions, NEA maintains a global footprint and active involvement in the United States, Asia and other regions, supporting companies throughout their growth lifecycle.

Invus is a global investment firm founded in 1985 that builds lasting value by partnering with management teams to transform industries. It employs a flexible, long-term approach, aligning incentives with entrepreneurs and investors, and providing capital and strategic guidance to support growth through cycles. The firm invests directly in companies and makes selective co-investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, and education. With a patient mindset and emphasis on backing owner-managers, Invus seeks opportunities where its involvement adds strategic value beyond capital. It maintains offices in New York, London, Paris, and Hong Kong and operates a substantial evergreen capital base to sustain support for portfolio companies over extended horizons.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven companies, particularly in life sciences, biotechnology and related technologies. It backs early-stage ventures co-founded by scientists and entrepreneurs, and provides strategic guidance, expertise, and a broad network to translate academic and national-lab innovations into commercial products. The firm operates from Chicago and Seattle and has raised more than $3 billion across ten venture funds and invested in more than 150 companies.

Khosla Ventures is a California-based venture capital firm founded in 2004 and headquartered in Menlo Park. It provides venture assistance, strategic advice, and capital to entrepreneurs and invests across stages in technology-driven sectors, including artificial intelligence, healthcare, sustainability, digital health, consumer technology, and related deep-tech fields. The firm seeks to back bold ideas with a long-term perspective, often partnering with founders to help scale innovative products and business models. It emphasizes support beyond funding, offering strategic guidance to build companies with durable value and focusing on transformative technologies that address large markets.

Accomplice is an early-stage venture capital firm headquartered in Cambridge, Massachusetts. It invests in technology startups across cybersecurity, esports, data analytics, SMB software, emerging hardware platforms, and marketplaces. The firm employs a community-driven approach, leveraging networks and platforms such as AngelList, Boston Syndicates, Maiden Lane, Spearhead, BOSS, Rev, and TUGG to identify and back founders. While the majority of its investments are in the Boston area, the portfolio spans the United States, Canada, and Europe. Formerly part of Atlas Venture, the technology group was renamed Accomplice in 2014 as the firm refined its focus on early-stage technology companies.

Third Rock Ventures is a Boston-based venture capital firm that concentrates on early-stage investments in life sciences and healthcare. It backs biotechnology, pharmaceuticals, medical devices, diagnostics, and related information technology companies with high growth potential, providing substantial initial capital and active support to accelerate development and commercial success. The firm emphasizes strategic collaborations and seeks meaningful involvement in portfolio companies, including potential leadership roles, to advance medicines, therapies, and diagnostics. By positioning its investments within the U.S. life sciences landscape, Third Rock Ventures aims to help startups translate scientific breakthroughs into clinically meaningful products and outcomes.

Spark Capital is a venture capital firm founded in 2005 with offices in San Francisco, Boston, and New York City. It provides early-stage and growth funding to startups across sectors including consumer, software, fintech, media, and internet services. The firm emphasizes a founder-friendly, collaborative approach and seeks to back ambitious teams that aim to reshape markets. Its portfolio includes notable companies such as Twitter, Discord, Oculus, Warby Parker, and Tumblr, illustrating a track record of supporting product-driven ventures across stages.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

Hyperplane Venture Capital is a Boston-based early-stage technology investment firm that backs exceptional founders building machine intelligence and data-driven companies. The firm concentrates on startups leveraging artificial intelligence, machine learning, sensor technology, cloud computing, automation, robotics, and related areas, seeking solutions at the intersection of perception, communication, intelligence, and insight. It often makes early checks and emphasizes long-term partnerships to help portfolio companies scale from inception toward enduring market impact. Portfolio focus includes AI-enabled infrastructure, autonomous systems, robotics, secure collaboration, supply chain visibility, and other AI-powered workflows across diverse industries. The firm partners with founders to shape solutions and build durable, iconic businesses where AI intersects with real-world workflows and infrastructure.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

SOSV is a global venture capital firm focused on deep tech investments that address human and planetary health, backing seed-to-growth startups and delivering hands-on programs that accelerate product development, customer acquisition, and fundraising. It operates accelerator-like facilities for deep tech founders, including IndieBio in San Francisco and New York (referred to as SOSV SF & NY) and HAX in Newark, offering labs, offices, engineering support, mentorship, and broad access to an investor network. With a large and active portfolio across dozens of countries, SOSV supports hundreds of pre-seed and follow-on investments annually from its New Jersey base and through its global network, emphasizing long-term founder support beyond initial funding and fostering collaboration among portfolio companies and investors.

Safar Partners is a venture capital investment firm based in Cambridge, Massachusetts, founded in 2018. It funds technology companies at seed to growth stages in sectors including cleantech, advanced materials, artificial intelligence and information technology, robotics, and life sciences. The firm sources opportunities through deep relationships with leading universities such as MIT, Harvard, and the University of Rochester, and provides guidance to portfolio companies as they scale. Safar Partners operates as a registered investment adviser and emphasizes applying ESG considerations within its investment approach.

.406 Ventures is a Boston-based venture capital firm that focuses on early-stage investments in information technology, security and infrastructure, software, and technology-enabled business services, with a strong emphasis on cybersecurity, cloud software, digital health, data analytics, fintech, AI and big data. The firm primarily backs B2B and enterprise IT companies and often acts as lead or first institutional investor, seeking to partner with founders to scale growth. It targets companies in the Northeast United States, beginning with initial commitments typically between $2 million and $5 million and total investments between $6 million and $10 million per company, with follow-on support as the company grows. The team emphasizes hands-on involvement, leveraging deep industry experience and networks to help portfolio companies succeed, including board representation. Founded in 2005 and headquartered in Boston, the firm combines operational know-how with capital to create value for entrepreneurs and investing partners.

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. The firm focuses on investing in life sciences, diagnostics, digital health, health technology, AI and machine learning, and related technology sectors, supporting breakthrough science and technology-driven companies from early to growth stages. Its portfolio targets companies that aim to deliver meaningful advances in healthcare and technology, and the firm emphasizes building a better tomorrow through strategic capital and resources that help entrepreneurs develop and scale impactful solutions across life sciences, technology and affiliated industries.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

Pillar VC is a Boston-based venture capital firm founded in 2016 that backs early-stage companies, often partnering with founders from inception. It was co-founded by CEOs who built successful companies such as Wayfair, Ginkgo Bioworks, DraftKings, Abridge, ButcherBox and Flywire. The firm concentrates on technically ambitious ventures in artificial intelligence, biotechnology and other deep-tech areas, seeking breakthroughs that could define the future. Pillar VC manages significant capital and has raised multiple funds, including Fund IV, and its portfolio spans more than 90 companies, about half with university roots. Notable holdings include Neural Magic (acquired by Red Hat), Abridge and Latent Labs. In addition to investing, Pillar VC provides resources for startups, such as pitch deck templates and financial models, and emphasizes support from inception to scale. The firm aims to fuel a new era of rapid scientific and technological advancement from its Boston base.

Launchpad Venture Group is a Boston-based angel investor network that provides financial and human capital to early-stage science and technology startups. Founded in 2001, it supports ventures across software, information technology, web and mobile sectors, medical devices and diagnostics, healthcare IT, networking and telecom, and clean-tech and renewable energy, with a focus on U.S. opportunities in New England. The group emphasizes mentorship alongside funding, seeking to build long-term relationships with innovative founders. Through its network, Launchpad Venture Group connects portfolio companies to potential customers, service providers, partners, and future sources of financing. It has invested more than $125 million in over 150 startups, aiming to help entrepreneurs scale and succeed.

Beacon Angels is a Boston-based angel investment group that backs early-stage, fast-growing companies in New England. It provides capital and strategic support to entrepreneurs, with regular monthly meetings to review opportunities. Membership is open to accredited investors seeking portfolio growth, and the group is a member of the Angel Capital Association.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, investing in seed and early-stage companies as well as growth opportunities, and has backed influential firms such as Apple Computer, Intel, Illumina, Nest, and SlideShare. The firm supports portfolio companies across information technology, life sciences, software, cybersecurity, and emerging technologies, pursuing disruptive innovations and long-term growth through partnerships with entrepreneurs to build enduring companies.

Samsara BioCapital is a biotechnology-focused venture capital firm based in Palo Alto, California, established in 2016. The firm concentrates on funding and supporting biotechnology companies and transformative therapeutics across the United States, leveraging multidisciplinary expertise and strategic partnerships to accelerate clinical and commercial breakthroughs. As a registered investment adviser, Samsara BioCapital combines scientific insight with strategic resources to help entrepreneurs advance innovative medicines.

CVP Management is a venture capital firm focused on early‑stage technology investments, including seed and early Series A rounds. It concentrates on information technology infrastructure with emphasis on software applications, internet, digital media, digital marketing, vertical SaaS, cloud, embedded software, mobile, and financial services technologies. The firm typically invests from $0.1 million to $1 million, and for seed and Series A rounds from $1 million to $3.5 million, in companies with an enterprise value around $5 million. It prefers to hold a seat on the portfolio company board and to invest in preferred stock. The firm funds companies located in the Northeast corridor, especially Boston, New York, and Toronto, and began operation on June 1, 1998, with headquarters in Cambridge, Massachusetts, and an additional office in Boston.

CRV is a Palo Alto–based early-stage venture capital firm that traces its roots to 1970 as Charles River Ventures. The firm pursues a hands-on, value-added approach to back seed through Series B technology, consumer, healthcare and enterprise companies across North America. With a long history as one of the industry’s oldest venture firms, CRV emphasizes deep collaboration with founders, mentorship on strategy, product development, customer acquisition and IP protection to help portfolio companies reach growth milestones. It maintains offices in Cambridge, Massachusetts, and Menlo Park, California, and has supported a broad set of startups that have gone on to become category leaders. CRV aims to act as a trusted, long-term partner beyond capital, guiding companies from inception to IPO and beyond.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

E14 Fund is a Cambridge, Massachusetts based venture capital firm that backs early-stage technology startups, with a focus on ventures originating from MIT and related research ecosystems. It typically invests from pre-seed to seed and into early Series A rounds across fields such as artificial intelligence, robotics, biotechnology, manufacturing, and smart infrastructure. The firm leverages a broad network of advisors, investors, and entrepreneurs to help portfolio companies move technologies from the lab to the market, scale operations, and attract further funding. It emphasizes community building and inclusivity, supporting diverse founders and offering resources to help entrepreneurs connect with opportunities and talent.

Boston Seed Capital is a venture capital firm based in the Boston area, with a Wellesley Hills, Massachusetts office, that provides seed- and early-stage funding to internet-enabled startups across the United States. It focuses on consumer goods, business services, and technology, including information technology, SaaS, cybersecurity, e-commerce, big data, marketplaces, artificial intelligence and machine learning, and esports. The firm adopts a hands-on, founder-focused approach, collaborating with entrepreneurs from concept through scale, drawing on experience in supporting both consumer and business-to-business software ventures. Founded in 2010, it aims to help early-stage companies grow in a competitive technology landscape.

Refactor Capital is a Burlingame, California-based venture capital firm that makes seed-stage investments in hard-tech and biotechnology startups across the United States. Led by solo general partner Zal Bilimoria, the firm typically writes early checks in the range of $1–$2 million. It backs founders developing transformative technologies across sectors such as artificial intelligence, infrastructure, applied biology, energy, aerospace, earth systems, manufacturing, and critical materials. Its portfolio includes Solugen, Astranis, and Coinbase. Refactor Capital aims to be the first investment source for promising startups, focusing on backing founders who refactor the real world.

Lux Capital is a venture capital firm founded in 2000 with offices in New York City and Silicon Valley. It invests in seed- and early-stage ventures, and in select later-stage opportunities, across science-driven sectors such as artificial intelligence, biotechnology, biochemistry, materials science, electronics, space, infrastructure, and aerospace, including areas like 3D printing, flying and surgical robotics, genomics, satellites, drones, and computational imaging. Lux backs technical founders and research-driven teams, providing capital alongside strategic input on product development, company building, and long-term positioning to translate scientific research into scalable businesses. The firm emphasizes opportunities grounded in underlying science, potential industry impact, and feasibility of execution over extended horizons, with an active approach to helping entrepreneurs build successful, high-growth companies. Lux manages approximately $4 billion in assets focused on seed, early-stage, and growth investments across the physical, material, and life sciences, and its investment team has built more than 20 companies from scratch.

Fontinalis Partners is a Detroit- and Boston-based venture capital firm focused on next-generation mobility and related technology. Founded in 2009, the firm backs early-stage through growth opportunities across the mobility ecosystem, including connected vehicles, data and analytics, intelligent infrastructure, location-based services, mobility transactions, and new mobility models such as car sharing and ride-hailing, as well as software, SaaS, and cloud-based solutions. Fontinalis pursues an intermodal approach across road, rail, air, maritime, and other modes. The team leverages management experience, market access, strategic relationships, and international expertise to support portfolio companies as a strategic partner. Investments range across seed to late-stage rounds, with a preference for board seats and a willingness to fund opportunities throughout the lifecycle. Fontinalis operates independently and is not affiliated with a single automaker.

Longwood Fund is a Boston-based venture capital firm that backs science-driven healthcare and life sciences companies. Founded in 2010, it targets solutions for serious medical problems and often collaborates with technology originating from leading labs such as Harvard and MIT. The firm positions itself as a value-add investor, working closely with portfolio companies to translate research into patient therapies, with partners actively engaging as co-founders or senior executives when appropriate. Its focus spans healthcare, pharmaceuticals, biotechnology, and oncology, aiming to accelerate the journey from lab discovery to clinical impact.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. As a venture capital investor and registered investment adviser, it partners with entrepreneurs developing novel medicines and life-saving therapeutics, supporting discovery and development through long-term collaborations. The firm emphasizes a molecular understanding of biology and chemistry to identify promising opportunities with potential patient impact, investing across early-stage and later-stage biotech companies. It backs innovative ventures addressing unmet medical needs and aims to accelerate translational research to bring transformative therapeutics to patients.

Andreessen Horowitz is a venture capital firm founded in 2009 and headquartered in Menlo Park, California. It deploys capital across the full startup lifecycle, from seed to growth, and invests in a broad range of sectors including artificial intelligence, healthcare, consumer technology, fintech, cryptocurrency and blockchain, enterprise software, and infrastructure. The firm offers more than funding, providing an operating network that connects portfolio companies with technical advisors, executive talent, and industry operators to support growth and scale. Through its thought leadership and wide industry coverage, Andreessen Horowitz positions itself as a principal investor in technology-driven companies shaping software-enabled markets.

NextView Ventures is a venture capital firm founded in 2010 that makes seed and early‑stage investments focused on North America. Headquartered in Boston with offices in New York City and San Francisco, the firm backs startups across sectors such as fintech, health, food and beverage, apparel, transportation, media and entertainment, ecommerce, software, and other business‑focused technologies. It pursues a high‑conviction, hands‑on approach, helping entrepreneurs from inception to scale through mentorship and practical resources, and it maintains a strong emphasis on founder support and collaboration. Notable investments include Seneca, Bobbie, and WHOOP, reflecting a commitment to backing innovative companies with potential for significant impact. The firm also engages with the entrepreneurial community through founder resources, blogs, podcasts, newsletters, and events, reinforcing its role as an active partner to founders rather than a passive investor.

LaunchCapital is a venture capital firm founded in 2008 that provides seed and early-stage funding across diverse industries, with a hands-on approach that includes mentorship and ongoing support for portfolio companies. Backed by prominent family offices such as the Pritzker/Vlock Family Office, it has invested in over 200 companies and pursues opportunities nationwide. The firm operates via two investment vehicles: LaunchCapital Ventures, which provides equity for growth opportunities, and LaunchCapital Small Business, which blends equity and debt to support near-term revenue and local or regional growth. Based in New Haven, Connecticut, LaunchCapital focuses on technology, consumer, and medical sectors, and seeks opportunities in commerce, marketplace, media, enterprise software and services, data, finance, healthcare, and related fields.

FJ Labs is a New York-based venture capital firm founded in 2015 by Fabrice Grinda. It specializes in marketplaces and consumer-facing startups and is stage-agnostic, making seed to Series A investments with typical checks ranging from 50,000 to 5,000,000. The firm backs founders pursuing network effects and scalable models across consumer internet, e-commerce, fintech, and related sectors, aiming to support transformative growth. Its portfolio includes companies such as Alibaba Group, Beepi, BrightRoll, Betterment, Adore Me, and Earnest, reflecting a broad approach to marketplaces and consumer ventures. FJ Labs emphasizes passion, execution, and tenacity in founders and actively seeks new opportunities to back impactful businesses.

Omega Funds is a Boston-based investment firm that focuses on life sciences and healthcare, including biotechnology, digital health, immunology, rare diseases, and oncology, with additional exposure to software-as-a-service. The firm pursues early-stage and venture investments in North America and Western Europe and maintains offices in Boston and Geneva. It operates as a registered investment adviser, offering strategic support to portfolio companies to advance medical products to patients.

Glasswing Ventures is a Boston-based early-stage venture capital firm founded in 2016 that invests in startups applying artificial intelligence and frontier technologies to enterprise and cybersecurity markets. It funds pre-seed to early-stage companies in the United States, with a focus on the East Coast, including Boston and New York. Typical investments range from roughly 1.5 to 3 million across 15 to 20 portfolio companies, and the firm differentiates itself through technical capabilities such as the AI Palette and Enterprise AI Value Creation Framework, along with a Building Partners model that provides startups with C-level expertise across key functions. Glasswing emphasizes backing founders pursuing impactful AI breakthroughs and actively engages with the AI community through insights, events, and advisory roles. The team leverages deep domain knowledge and advisory councils to help companies scale in enterprise software, automation, and cybersecurity markets.

Prelude Ventures is a venture capital firm based in San Francisco that invests in early-stage startups developing solutions to mitigate climate change. The firm focuses on sectors including built environment, carbon management, compute, energy, food and agriculture, manufacturing and industrials, and mobility, seeking category-defining companies that can scale to reduce greenhouse gas emissions. Founded in 2013, Prelude provides capital and strategic support to portfolio companies to accelerate climate innovation and create impactful, commercially viable businesses.

Castor Ventures is an investment firm that builds diversified venture portfolios by investing in a broad range of venture-backed companies, alongside established venture firms.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

Founders Fund is a San Francisco-based venture capital firm that supports science and technology companies across seed to late-stage investments, with a global reach and a focus on transformative technologies. It has backed notable companies such as SpaceX, Palantir, Facebook and Airbnb, and pursues a founder-friendly approach that provides substantial support with minimal interference across sectors including software, artificial intelligence, aerospace, energy, health, cybersecurity, biotechnology, quantum computing, and consumer internet.